Related Experiment Video
Updated: May 23, 2026
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Circulating biomarkers in advanced renal cell carcinoma: clinical applications
Maria Hernandez-Yanez1, John V Heymach, Amado J Zurita
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA. mhernandez8@mdanderson.org
Abstract:
Advances in understanding the biology of renal cell carcinoma (RCC) have resulted in treatment strategies based on molecularly targeted agents that have substantially improved the outcomes of patients with metastatic RCC. Agents targeting the vascular endothelial growth factor pathway and the mammalian target of rapamycin have shown efficacy in randomized clinical trials and received international approval for treating RCC. Multiple candidate biomarkers of the biologic activity of such targeted therapies as well as markers of treatment response and patients' prognosis are being evaluated to improve drug development and to identify patients who may obtain the greatest benefit from the various treatment options. This review summarizes recent developments in identifying circulating biomarkers of targeted therapies for metastatic RCC, including soluble proteins and circulating cells.
Insights
Targeted therapies have improved outcomes for metastatic renal cell carcinoma (RCC). This review focuses on identifying circulating biomarkers, including proteins and cells, to guide treatment and improve drug development for RCC patients.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Metastatic renal cell carcinoma (RCC) treatment has advanced with molecularly targeted agents.
- Vascular endothelial growth factor pathway and mTOR inhibitors are approved and effective therapies for RCC.
Purpose of the Study:
- To review recent developments in identifying circulating biomarkers for targeted therapies in metastatic RCC.
- To explore biomarkers for assessing treatment response and patient prognosis in RCC.
Main Methods:
- Literature review of recent studies on circulating biomarkers for metastatic RCC.
- Focus on soluble proteins and circulating cells as potential biomarkers.
Main Results:
- Targeted therapies, including VEGF and mTOR inhibitors, have shown significant efficacy in clinical trials for metastatic RCC.
- Ongoing evaluation of candidate biomarkers aims to personalize treatment and improve drug development.
- Circulating biomarkers, such as soluble proteins and cells, are key areas of investigation.
Conclusions:
- Advances in understanding RCC biology have led to effective targeted therapies.
- Circulating biomarkers are crucial for optimizing drug development and patient selection for metastatic RCC treatment.
- Continued research into biomarkers will further enhance personalized medicine approaches for RCC.
